IPOSchedule
EN
EnglishDeutschFrançais
2026 offering

INTERPACE BIOSCIENCES Uplisting

INTERPACE BIOSCIENCES provides molecular diagnostic testing and pathology services to support physicians assessing cancer risk.

  • IDXG
  • Nasdaq Capital Market
  • United States
  • Healthcare
Filed 25 Sept 2026

This page records the company’s public listing process. Figures and dates are shown when verified from the linked sources.

Last verified 4 Oct 2026

Company overview

INTERPACE BIOSCIENCES website

The company develops and commercializes genomic tests. These tests are intended to personalize medicine and help improve patient diagnosis and management, including for patients with indeterminate biopsies and clinical features associated with perceived cancer risk.

Company country
United States

Offering details

Base offering, before overallotment

Exchange
Nasdaq Capital Market
Ticker
IDXG
Shares offered
3,100,000
Shares after offering
9,001,962

Listing timeline

  1. Registration filed
  2. Proposed terms published

Filings and documents

Other IPO profiles

Industrials01

VME Companies

VME Companies provides engineering, procurement and construction services and modular process systems and equipment.

IPO valuation$276M – $345M
Filings Nasdaq Capital MarketIPO
Industrials02

Helio Corp /FL/

Helio Corporation is a holding company providing technology, engineering, and research and development services.

Listing valuation$29.5M – $36.8M
Filings Nasdaq Capital MarketUplisting
Healthcare03

Neuro Spectrum Insights

Neuro Spectrum Insights develops software to support autism diagnosis through MRI image analysis.

IPO valuation$60.4M – $75.4M
Filings NYSE AmericanIPO